SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal

Status Recruiting

Clinical Trial Summary

The goal of this observational study is to utilize a novel imaging system designed for high-resolution retinal imaging of neonates, infants and children to identify the signs of photoreceptor development and degeneration in children with early-onset inherited retinal dystrophies (EORDs). Participants will have research imaging with SS-HH-OCT at the time of clinically-indicated eye examinations or procedures. The investigators aim to establish the basis for utilization of OCT imaging in earlier diagnosis and disease monitoring in children with EORDs. This work will set data reference standards and IRD endpoints that can be used in clinical trials.

Clinical Trial Description

What photoreceptor degenerative changes take place in children with early-onset inherited retinal dystrophies, and how is photoreceptor development in this patient population affected by genetic defects? Our novel investigational SS-HH-OCT system features high scanning speed, long laser wavelength, and an ergonomic light-weight handheld design. The investigators hypothesize that imaging with this system will enable us to characterize early-onset retinal dystrophies (EORD)-associated PDCs in young children. To this end, the investigators propose the following specific aims: Specific Aim 1: Optimize and demonstrate reproducibility of SS-HH-OCT imaging protocols to visualize photoreceptor development and degeneration in children with and without EORDs. Specific Aim 2: Use SS-HH-OCT parameters to characterize biomarkers of foveal photoreceptor development and degeneration in children with EORDs versus healthy controls. A total of 80 participants will be enrolled in this study. Participants' age between 0 through 8 years (<9 years). For children with EORD, successful completion of this study will result in 1) a framework for reproducible OCT imaging; 2) characterization of biomarkers of retinal degeneration; 3) establishment of reference data by genetic variants 4) insights into foveal development. Additionally, this study will set pilot data of structure-function data and timeline of photoreceptor degeneration for future NIH funded studies. ;

Study Design

Related Conditions & MeSH terms

Retinal Dystrophies

Clinical Trial Details

NCT number	NCT06177977
Study type	Interventional
Source	Duke University
Contact	Ramiro Maldonado, MD
Phone	(919) 684 5631
Email	ramiro.maldonado@duke.edu
Status	Recruiting
Phase	N/A
Start date	March 1, 2024
Completion date	December 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04123626` - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene	Phase 1/Phase 2
Completed	`NCT01546181` - Retinal Imaging by Adaptive Optics in Healthy Eyes and During Retinal and General Diseases
Recruiting	`NCT03592017` - Performance of Long-wavelength Autofluorescence Imaging	N/A
Recruiting	`NCT03853252` - iPS Cells of Patients for Models of Retinal Dystrophies	N/A
Recruiting	`NCT04855045` - An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene.	Phase 2/Phase 3
Completed	`NCT02983305` - Optical Head-Mounted Display Technology for Low Vision Rehabilitation	N/A
Not yet recruiting	`NCT06455826` - MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)	Phase 1
Recruiting	`NCT05573984` - Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
Completed	`NCT03763227` - Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy	Phase 2
Completed	`NCT04945772` - Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]	Phase 2
Recruiting	`NCT05218928` - Qualification for Cone-Optogenetics
Recruiting	`NCT05294978` - EyeConic: Qualification for Cone-Optogenetics
Completed	`NCT03843840` - Dual Wavelength OCT
Enrolling by invitation	`NCT06162585` - Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Recruiting	`NCT02014389` - Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer
Not yet recruiting	`NCT06319872` - The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs) — SS-HH-OCT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms